


## JZP-MA-13

Cat. No.:	HY-152152
Molecular Formula:	C <sub>14</sub> H <sub>15</sub> FN <sub>4</sub> O <sub>3</sub> S
Molecular Weight:	338.36
Target:	MAGL
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	JZP-MA-13 is a selective $\alpha/\beta$ -hydrolase domain 6 (ABHD6) inhibitor with an IC <sub>50</sub> of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 392 nM (ABHD6) <sup>[1]</sup>
<b>In Vitro</b>	JZP-MA-13 does not bind orthosterically to CB1 or CB2 or allosterically influences canonical CB1 or CB2 signaling <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Karine Mardon, et al. Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid  $\alpha/\beta$ -Hydrolase Domain 6 (ABHD6). J Med Chem. 2022 Dec 14.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA